The established chemokine-related prognostic gene signature in prostate cancer: Implications for anti-androgen and immunotherapies

Chen, Lei; Zheng, Yi; Jiang, Changqin; Yang, Cheng; Zhang, Li; Liang, Chaozhao

doi:10.3389/fimmu.2022.1009634

Cited by 7 publications

(6 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Transcriptomic data and survival information for 140 patients with PRAD were downloaded from the Memorial Sloan Kettering Cancer Centre project (MSKCC) using cBioPortal ( http://www.cbioportal.org/ ). We obtained the GSE70768 dataset from the NCBI GEO ( http://www.ncbi.nlm.nih.gov/geo ) public database [ 21 ]. This dataset contained data from 111 patients with PRAD, including their complete expression profiles and survival information.…”

Section: Methodsmentioning

confidence: 99%

Predicting prostate adenocarcinoma patients’ survival and immune signature: a novel risk model based on telomere-related genes

Zheng,

Chen,

et al. 2024

Discov Onc

View full text Add to dashboard Cite

Alterations in telomeres constitute some of the earliest occurrences in the tumourigenesis of prostate adenocarcinoma (PRAD) and persist throughout the progression of the tumour. While the activity of telomerase and the length of telomeres have been demonstrated to correlate with the prognosis of PRAD, the prognostic potential of telomere-related genes (TRGs) in this disease remains unexplored. Utilising mRNA expression data from the Cancer Genome Atlas (TCGA), we devised a risk model and a nomogram to predict the survival outcomes of patients with PRAD. Subsequently, our investigations extended to the relationship between the risk model and immune cell infiltration, sensitivity to chemotherapeutic drugs, and specific signalling pathways. The risk model we developed is predicated on seven key TRGs, and immunohistochemistry results revealed significant differential expression of three TRGs in tumours and paracancerous tissues. Based on the risk scores, PRAD patients were stratified into high-risk and low-risk cohorts. The Receiver operating characteristics (ROC) and Kaplan–Meier survival analyses corroborated the exceptional predictive performance of our novel risk model. Multivariate Cox regression analysis indicated that the risk score was an independent risk factor associated with Overall Survival (OS) and was significantly associated with T and N stages of PRAD patients. Notably, the high-risk group exhibited a greater response to chemotherapy and immunosuppression compared to the low-risk group, offering potential guidance for treatment strategies for high-risk patients. In conclusion, our new risk model, based on TRGs, serves as a reliable prognostic indicator for PRAD. The model holds significant value in guiding the selection of immunotherapy and chemotherapy in the clinical management of PRAD patients.

show abstract

Section: Methodsmentioning

confidence: 99%

Predicting prostate adenocarcinoma patients’ survival and immune signature: a novel risk model based on telomere-related genes

Zheng,

Chen,

et al. 2024

Discov Onc

View full text Add to dashboard Cite

show abstract

“…PCa purity and CD4 + T cells, CD8 + T cells, B, macrophage, dendritic, and neutrophil infiltration were associated with CXCL14 expression. The researchers additionally discovered that PCa pathology T stage and immunological score were significantly correlated with CXCL14 expression [ 221 ]. An earlier study found that CXCL14-expressing CAF and fibroblasts stimulated by CXCL14 upregulate NOS1.…”

Section: Chemokines/cxcrs and Pcamentioning

confidence: 99%

The role of proinflammatory cytokines and CXC chemokines (CXCL1–CXCL16) in the progression of prostate cancer: insights on their therapeutic management

Ullah,

Jiao,

Shen

2024

Cell Mol Biol Lett

View full text Add to dashboard Cite

Reproductive cancers are malignancies that develop in the reproductive organs. One of the leading cancers affecting the male reproductive system on a global scale is prostate cancer (PCa). The negative consequences of PCa metastases endure and are severe, significantly affecting mortality and life quality for those who are affected. The association between inflammation and PCa has captured interest for a while. Inflammatory cells, cytokines, CXC chemokines, signaling pathways, and other elements make up the tumor microenvironment (TME), which is characterized by inflammation. Inflammatory cytokines and CXC chemokines are especially crucial for PCa development and prognosis. Cytokines (interleukins) and CXC chemokines such as IL-1, IL-6, IL-7, IL-17, TGF-β, TNF-α, CXCL1–CXCL6, and CXCL8–CXCL16 are thought to be responsible for the pleiotropic effects of PCa, which include inflammation, progression, angiogenesis, leukocyte infiltration in advanced PCa, and therapeutic resistance. The inflammatory cytokine and CXC chemokines systems are also promising candidates for PCa suppression and immunotherapy. Therefore, the purpose of this work is to provide insight on how the spectra of inflammatory cytokines and CXC chemokines evolve as PCa develops and spreads. We also discussed recent developments in our awareness of the diverse molecular signaling pathways of these circulating cytokines and CXC chemokines, as well as their associated receptors, which may one day serve as PCa-targeted therapies. Moreover, the current status and potential of theranostic PCa therapies based on cytokines, CXC chemokines, and CXC receptors (CXCRs) are examined.

show abstract

“…Transcriptomic data and survival information for 140 patients with PRAD were downloaded from the Memorial Sloan Kettering Cancer Centre project (MSKCC) using cBioPortal (http://www.cbioportal.org/). We obtained the GSE70768 dataset from the NCBI GEO (http://www.ncbi.nlm.nih.gov/geo) public database [21]. This dataset contained data from 111 patients with PRAD, including their complete expression pro les and survival information.…”

Section: Data Acquisition and Preprocessingmentioning

confidence: 99%

Predicting Prostate Adenocarcinoma Patients’ Survival and Immune Signature: A Novel Risk Model Based on Telomere-Related Genes

Zheng,

Chen,

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Telomere-related genes (TRGs) play an essential role in the carcinogenesis and progression of prostate adenocarcinoma(PRAD). However, the prognostic value of TRGs remains unclear in PRAD. Methods We conducted a study using The Cancer Genome Atlas-Prostate Adenocarcinoma (TCGA-PRAD) dataset as the training group and the Memorial Sloan-Kettering Cancer Center (MSKCC) and Gene Expression Omnibus (GEO) datasets as the validation group. We developed a risk model and a nomogram to predict survival rates in patients with PRAD. The expression of model genes and their possible regulatory mechanisms were then analyzed. Furthermore, we explored the relationship between the risk model and immune cell infiltration, chemotherapy drug sensitivity, and specific signaling pathways using the CIBERSORT algorithm, the Genomics of Drug Sensitivity in Cancer (GDSC) database, and motif enrichment. Results The developed risk model was based on seven key TRGs (HELLS, TOP3A, SRC, LARP7, BUB3, THRSP, and GTF2H4). Moreover, this model was an independent prognostic factor for patients with PRAD and was significantly associated with T and N stages. Among seven TRGs, TOP3A and BUB3 were not only significantly positively correlated with the clinical T and N phases of PRAD, but also expression was significantly increased in PRAD tissues compared to adjacent normal tissues. The model was a good predictor of 1-, 3-, and 5-year survival, and patients in the high-risk group had significantly shorter overall survival than those in the low-risk group. The integrated nomogram can be a good predictor of 3- and 5-year survival in patients with PRAD. Finally, compared to the low-risk group, the high-risk group had a higher response to chemotherapy and immunosuppression, which provided potential guidance to treatment options for patients in the high-risk group. Conclusion In summary, a new risk model based on TRGs was successfully developed in PRAD. This risk model is valuable for guiding the selection of immunotherapy and chemotherapy in the clinical treatment of patients with PRAD.

show abstract

The established chemokine-related prognostic gene signature in prostate cancer: Implications for anti-androgen and immunotherapies

Cited by 7 publications

References 47 publications

Predicting prostate adenocarcinoma patients’ survival and immune signature: a novel risk model based on telomere-related genes

Predicting prostate adenocarcinoma patients’ survival and immune signature: a novel risk model based on telomere-related genes

The role of proinflammatory cytokines and CXC chemokines (CXCL1–CXCL16) in the progression of prostate cancer: insights on their therapeutic management

Predicting Prostate Adenocarcinoma Patients’ Survival and Immune Signature: A Novel Risk Model Based on Telomere-Related Genes

Contact Info

Product

Resources

About